

# Agendia Scientific Presentations at SABCS 2018



## WEDNESDAY, DECEMBER 5, 2018

1. MammaPrint, Blueprint, and full-genome data linked with clinical data to evaluate new gene expression profiles (FLEX).  
Brufsky AM, Crozier JA, Grady I, et al.  
**POSTER:** OT1-13-01  
**ONGOING TRIALS 1** (Hall 1, 5.00 PM – 7.00 PM):  
Genomic Signatures
2. Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with locally advanced triple negative breast cancer.  
Yuan Y, Frankel P, Li M, et al.  
**POSTER:** P1-15-07  
**ONGOING TRIALS 1** (Hall 1, 5.00 PM – 7.00 PM):  
Treatment: Neoadjuvant Chemotherapy

## THURSDAY, DECEMBER 6, 2018

3. Blueprint molecular subtyping versus HER2 assessment by immunohistochemistry and FISH in the real-world diagnostic setting.  
Treece T, Audeh W, Navarro F, et al.  
**POSTER:** P3-10-22  
**POSTER SESSION 3** (Hall 1, 5.00 PM – 7.00 PM):  
Prognostic and Predictive Factors:  
Predictive Biomarkers for Targeted Therapies
4. Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: Lessons from ~1000 patients across 10 arms of the I-SPY 2 TRIAL.  
Wolf DM, Yau C, Wulfkuhle J, et al.  
**POSTER:** P3-10-02  
**POSTER SESSION 3** (Hall 1, 5.00 PM – 7.00 PM):  
Prognostic and Predictive Factors:  
Predictive Biomarkers for Targeted Therapies
5. Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ~1000 patients across 10 therapies.  
Wolf DM, Yau C, Wulfkuhle J, et al.  
**POSTER:** P3-10-06  
**POSTER SESSION 3** (Hall 1, 5.00 PM – 7.00 PM):  
Prognostic and Predictive Factors:  
Predictive Biomarkers for Targeted Therapies
6. LIV-1 expression in primary breast cancers in the I-SPY 2 TRIAL.  
Yau C, Brown-Swigart L, Asare S, et al.  
**POSTER:** P3-10-13  
**POSTER SESSION 3** (Hall 1, 5.00 PM – 7.00 PM):  
Prognostic and Predictive Factors:  
Predictive Biomarkers for Targeted Therapies

## FRIDAY, DECEMBER 7, 2018

### SPOTLIGHT PRESENTATION

7. Metabolic syndrome increases risk of recurrence and impacts immune pathways in invasive lobular carcinoma.  
Robinson P, Treece T, Osipo C, et al.  
**POSTER DISCUSSION:** PD7-04  
**SPOTLIGHT SESSION 7** (Stars at Night Ballroom 1 & 2, 7.00 AM – 9.00 AM): Lobular Breast Cancer

### SPOTLIGHT PRESENTATION

8. Molecular subtypes of invasive lobular breast cancer in the I-SPY2 TRIAL.  
Zhu Z, Yau C, Chien AJ, et al.  
**POSTER DISCUSSION:** PD7-06  
**SPOTLIGHT SESSION 7** (Stars at Night Ballroom 1 & 2, 7.00 AM – 9.00 AM): Lobular Breast Cancer

FRIDAY, DECEMBER 7, 2018

### SPOTLIGHT PRESENTATION

9. Neoadjuvant chemotherapy for breast cancer: Nodal downstaging is highly correlated with pathological complete response.

Blumencranz P, Habibi M, Treece T, et al.

**POSTER DISCUSSION:** PD8-04

**SPOTLIGHT SESSION 8** (Stars at Night Ballroom 3 & 4, 7.00 AM – 9.00 AM): Local Regional Therapy

11. MammaPrint identifies 46% of patients, age ≤50 years with oncotype RS 18-30, as low risk and safe to forgo chemotherapy.

Soliman H, Lo S, Qamar R, et al.

**POSTER:** P4-08-10

**POSTER SESSION 4** (Hall 1, 7.30 AM – 9.00 AM): Prognostic and Predictive Factors: Prognostic Factors — Clinical Testing and Validation

13. Decentralized beta testing of MammaPrint and Blueprint NGS kit at University Hospitals Leuven and Curie Institute.

Slembrouck L, Laurent C, Delahaye LJ, et al.

**POSTER:** P4-08-25

**POSTER SESSION 4** (Hall 1, 7.30 AM – 9.00 AM): Prognostic and Predictive Factors: Prognostic Factors — Clinical Testing and Validation

10. Comparison of breast cancer molecular subtyping by Immunohistochemistry and by Blueprint® next generation RNA sequencing-based test at University Hospitals Leuven and Curie Institute Paris.

Darrigues L, Slembrouck L, Mittempergher L, et al.

**POSTER:** P4-02-07

**POSTER SESSION 4** (Hall 1, 7.30 AM – 9.00 AM): Detection/Diagnosis: Diagnostic Pathology

12. Comparative analyses of the prognostic value of oncotype and mammaPrint using the National Cancer Database.

Ibraheem AF, Olopade O, Huo D.

**POSTER:** P4-08-12

**POSTER SESSION 4** (Hall 1, 7.30 AM – 9.00 AM): Prognostic and Predictive Factors: Prognostic Factors — Clinical Testing and Validation

14. Economic Impact of MammaPrint (70-gene signature) in a clinical high risk population: A 10yr Markov model, 6,000-patient retrospective analysis of US claim data.

Blumencranz LE, Høst-Ragab A, Retèl VP et al.

**POSTER:** P5-15-08

**POSTER SESSION 5** (Hall 1, 7.30 AM – 9.00 AM): Psychosocial, QOL, and Educational Aspects: Cost Effectiveness

**VISIT BOOTH #607** to learn more about the MammaPrint and Blueprint tests for early-stage breast cancer

